Year: 2016
Type: other
Abstract: Radionuclides conjugated to antibodies are known as radioimmunotherapy (RIT). Cancer RIT is a subspecialty of radiation oncology and nuclear medicine. Radioisotopes are chosen based on half-life, energy path length, and ability to conjugate radioisotope to the tumor target without altering the target. For solid tumors, the radiolabeled antibody research is more varied but with limited clinical success. Solid tumors, unlike hematologic tumors, have a diversity of cells in their tumor deposits (i.e., hypoxic areas) and RIT may not penetrate beyond a few tumor cell layers, thus leaving the burden of tumor intact. RIT radiation is low-dose radiation (LDR) and has been shown to deliver radiation at approximately 0.3 Gy/h. For bone marrow transplants in hematology, the combination of RIT, chemotherapy, and external beam radiation therapy (EBRT) is being used to maximally cytoreduce and improve relapse rates. The most common route of administration of RIT is intravenously.
Authors: Savita V. Dandapani, Jeffrey Wong
Institutions: City Of Hope National Medical Center, City of Hope
Language: Malay
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4254055543